Asterias Biotherapeutics (AST) Reports Exclusive License Agreement with Regents of University of California; Begins Second Pre-Clinical Collaboration Initiated to Test Efficacy of AST-OPC1
Tweet Send to a Friend
Asterias Biotherapeutics, Inc. (NYSE: AST) today announced that it has entered into an exclusive license agreement with The Regents of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
